ABSTRACT
We studied safety and clinical efficacy of transplantation of autologous bone marrow cell in complex therapy of 158 patients with chronic hepatitis and cirrhosis of the liver. The efficiency of cell therapy was assessed in 12 months after single injection of the cells. The positive response (alleviation of liver cirrhosis or stabilization of the pathological process) was observed in 70% cases. The efficacy of therapy correlated with the severity and etiology of the disease and was maximum in patients with Child-Pugh class A (in 82.5% cases) and class B liver cirrhosis (in 79% cases); in patients with class C liver cirrhosis, the positive response was achieved in 42.5% cases. In 39 patients, ultrasonic examination performed in 3 years after transplantation revealed no focal lesions or ectopic ossification foci.
Subject(s)
Bone Marrow Transplantation/methods , Cell- and Tissue-Based Therapy/methods , Hepatitis, Chronic/therapy , Liver Cirrhosis/therapy , Adolescent , Adult , Aged , Bone Marrow Cells/cytology , Bone Marrow Transplantation/adverse effects , Female , Hepatitis, Chronic/pathology , Humans , Liver/pathology , Liver Cirrhosis/pathology , Male , Middle Aged , Transplantation, Autologous , Treatment Outcome , Young AdultABSTRACT
The Budd-Chiari syndrome is a rare disease associated with occlusion of the hepatic vein by a tumor or a thrombus. It develops due to progressive narrowing or occlusion of the hepatic veins and may occasionally proceed through the chronic disease within months, rarely years as individual recurrences, with pains, enlarged liver, and mild jaundice. These patients generally have partial hepatic vein occlusion. The paper describes a long (more than 20 years) course of the Budd-Chiari syndrome in which only a special angiographic study could verify the presumptive diagnosis and reveal the cause of evolving liver cirrhosis.
Subject(s)
Budd-Chiari Syndrome/diagnosis , Liver Cirrhosis/etiology , Angiography , Budd-Chiari Syndrome/complications , Diagnosis, Differential , Disease Progression , Endoscopy, Gastrointestinal , Humans , Liver Cirrhosis/diagnosis , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
The data characterizing tolerance and efficiency of autologous bone marrow cells in the treatment of patients with cirrhosis of the liver are presented. Injection of autologous bone marrow cells was not associated with the development of adverse reactions. Cell therapy of patients with compensated cirrhosis arrested asthenic syndrome, reduced cytolysis, increased the level of serum albumin and platelet count. Ultrasonic examination revealed reduction of portal hypertension (the area of the spleen and the portal vein lumen decreased). In patients with decompensated cirrhosis, a positive response presenting as reduction of the disease severity (by 1.9 points) was observed in 48.6% cases. Positive shifts in these patients were associated with a decrease of ALT and AST levels, reduction of laboratory signs of cirrhosis, increase in platelet count, and reduction of the asthenic syndrome. Hence, therapy with autologous bone marrow cells is safe and, according to preliminary results, can be regarded as a new approach to the treatment of patients with cirrhosis of the liver.
Subject(s)
Bone Marrow Transplantation/methods , Liver Cirrhosis/surgery , Adolescent , Adult , Alanine Transaminase/blood , Antigens, CD34/blood , Aspartate Aminotransferases/blood , Bone Marrow Transplantation/adverse effects , Female , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Liver Cirrhosis/blood , Liver Cirrhosis/pathology , Male , Middle Aged , Transplantation, Autologous , Treatment OutcomeABSTRACT
Clinical trails of Befnorin based on the human recombinant TNF-beta elaborated at the Research Design and Technology Institute of Biologically Active Substances, "Vector" State Research Center of Virology and Biotechnology, were carried out on healthy volunteers in compliance with a decision passed by the Committee of Medical and Immunobiological Preparations, Russia's Health Ministry. Single Befnorin doses of 5-10(4) U, 10(5) U, 5-10(5) U, and 10(6) U were administered as intramuscular injections. Clinical, biochemical and immunological parameters were registered for 7 days after a single dose. The drug had an impact on the below immunity indices: Fc-phagocytosis of monocytes, migration index and migration inhibition index. The dose of 10(5) U was proven to be most effective and safe. Supposedly, the drug can be effective in the treatment of herpetic diseases.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/adverse effects , Lymphotoxin-alpha/administration & dosage , Lymphotoxin-alpha/adverse effects , Adolescent , Adult , Dose-Response Relationship, Drug , Fever/chemically induced , Headache/chemically induced , Herpes Zoster/immunology , Humans , Injections, Intramuscular , Lymphocytes/drug effects , Middle Aged , Phagocytosis/drug effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effectsABSTRACT
AIM: To study changes in immune system of patients with various forms of chronic bronchitis (CB) and neurocirculatory asthenia (NCA). MATERIAL AND METHODS: Neurological and immunological examinations were made in 84 patients with CB exacerbation and 51 control subjects. RESULTS: It was found that 60% of CB patients had NCA. No negative effects of NCA on immune system in CB patients were registered. Suppression of immune system and secondary immunodeficiency occurred more frequently in CB patients without signs of NCA. 40% of CB patients had vagotonic NCA in which immunological disorders manifested most clearly. CONCLUSION: Vegetative disorders in CB patients do not affect immunological system. Functional testing of autonomic nervous system is suggested for prediction of immune system condition.
